Sec Form 4 Filing - BVF PARTNERS L P/IL @ Kymera Therapeutics, Inc. - 2026-06-24

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person BVF PARTNERS L P/IL 2. Issuer Name and Ticker or Trading Symbol Kymera Therapeutics, Inc. [ KYMR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) X __ Other (specify below) See Remarks and Footnotes (Last) (First) (Middle) 44 MONTGOMERY STREET, 40TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 06/24/2026 (Street) SAN FRANCISCO, CA94104 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, $0.0001 par value ( 1 ) 2,798,795 D ( 2 ) Common Stock, $0.0001 par value ( 1 ) 2,219,858 D ( 3 ) Common Stock, $0.0001 par value ( 1 ) 353,412 D ( 4 ) Common Stock, $0.0001 par value ( 1 ) 130,645 I ( 5 ) See footnote ( 5 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) ( 6 ) $ 99.87 06/24/2026 A 6,068 ( 7 ) 06/23/2036 Common Stock, $0.0001 par value 6,068 $ 0 6,068 I ( 6 ) See footnote ( 6 ) Pre-Funded Warrants to Purchase Common Stock ( 1 ) $ 0.0001 ( 8 ) ( 8 ) Common Stock, $0.0001 par value 201,546 201,546 D ( 2 ) Pre-Funded Warrants to Purchase Common Stock ( 1 ) $ 0.0001 ( 8 ) ( 8 ) Common Stock, $0.0001 par value 156,742 156,742 D ( 3 ) Pre-Funded Warrants to Purchase Common Stock ( 1 ) $ 0.0001 ( 8 ) ( 8 ) Common Stock, $0.0001 par value 550,425 550,425 D ( 2 ) Pre-Funded Warrants to Purchase Common Stock ( 1 ) $ 0.0001 ( 8 ) ( 8 ) Common Stock, $0.0001 par value 375,856 375,856 D ( 3 ) Pre-Funded Warrants to Purchase Common Stock ( 1 ) $ 0.0001 ( 8 ) ( 8 ) Common Stock, $0.0001 par value 52,733 52,733 D ( 4 ) Pre-Funded Warrants to Purchase Common Stock ( 1 ) $ 0.0001 ( 8 ) ( 8 ) Common Stock, $0.0001 par value 27,797 27,797 I ( 5 ) See footnote ( 5 ) Stock Option (Right to Buy) ( 6 ) $ 20 ( 9 ) 08/19/2030 Common Stock, $0.0001 par value 40,127 40,127 I ( 6 ) See footnote ( 6 ) Stock Option (Right to Buy) ( 6 ) $ 49.1 ( 9 ) 06/15/2031 Common Stock, $0.0001 par value 20,063 20,063 I ( 6 ) See footnote ( 6 ) Stock Option (Right to Buy) ( 6 ) $ 14.18 ( 9 ) 06/14/2032 Common Stock, $0.0001 par value 12,000 12,000 I ( 6 ) See footnote ( 6 ) Stock Option (Right to Buy) ( 6 ) $ 27.67 ( 9 ) 06/14/2033 Common Stock, $0.0001 par value 12,000 12,000 I ( 6 ) See footnote ( 6 ) Stock Option (Right to Buy) ( 6 ) $ 31.2 ( 9 ) 06/17/2034 Common Stock, $0.0001 par value 16,000 16,000 I ( 6 ) See footnote ( 6 ) Stock Option (Right to Buy) ( 6 ) $ 46.47 ( 9 ) 06/24/2035 Common Stock, $0.0001 par value 16,000 16,000 I ( 6 ) See footnote ( 6 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other BVF PARTNERS L P/IL 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA94104 X See Remarks and Footnotes BIOTECHNOLOGY VALUE FUND L P 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA94104 X See Remarks and Footnotes BVF I GP LLC 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA94104 X See Remarks and Footnotes BIOTECHNOLOGY VALUE FUND II LP 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA94104 X See Remarks and Footnotes BVF II GP LLC 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA94104 X See Remarks and Footnotes Biotechnology Value Trading Fund OS LP P.O. BOX 309 UGLAND HOUSE GRAND CAYMANKY1-1104 X See Remarks and Footnotes BVF Partners OS Ltd. P.O. BOX 309 UGLAND HOUSE GRAND CAYMANKY1-1104 X See Remarks and Footnotes BVF GP HOLDINGS LLC 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA94104 X See Remarks and Footnotes BVF INC/IL 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA94104 X See Remarks and Footnotes LAMPERT MARK N 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO, CA94104 X See Remarks and Footnotes Signatures BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 06/25/2026 Signature of Reporting Person Date Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 06/25/2026 Signature of Reporting Person Date BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 06/25/2026 Signature of Reporting Person Date Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 06/25/2026 Signature of Reporting Person Date BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 06/25/2026 Signature of Reporting Person Date BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 06/25/2026 Signature of Reporting Person Date Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 06/25/2026 Signature of Reporting Person Date BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 06/25/2026 Signature of Reporting Person Date BVF Inc., By: /s/ Mark N. Lampert, President 06/25/2026 Signature of Reporting Person Date /s/ Mark N. Lampert 06/25/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 ) This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. ( 2 )Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. ( 3 )Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. ( 4 )Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. ( 5 )Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account. ( 6 )Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. ( 7 )The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. ( 8 )The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire. ( 9 )The shares subject to the option have fully vested.

Remarks: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.